These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Aug 6, 2020Commercialization and launch of first royalty bearing products position company for next phase of growth
SAN DIEGO, August 6, 2020 — Pfenex Inc. (NYSE American: PFNX) reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The second quarter of 2020...
-
Jul 20, 2020
SAN DIEGO, July 20, 2020 — Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended June 30, 2020, after the market close on...
-
Jun 26, 2020
Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorization Pfenex’s commercial partner Adalvo entered into...
-
Jun 12, 2020Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States
SAN DIEGO, June 12, 2020 —Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States. Teriparatide...
-
Jun 5, 2020
SAN DIEGO, June 5, 2020 —Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William...
-
May 7, 2020
SAN DIEGO, May 7, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex...
-
Apr 24, 2020
SAN DIEGO, April 24, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market close on...
-
Apr 14, 2020FDA review for a Therapeutic Equivalency rating for PF708 continues
SAN DIEGO, April 14, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the Company’s...
-
Mar 11, 2020Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® | Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL | Earned $31.1 million in development and regulatory milestone payments in FY 2019
SAN DIEGO, March 11, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Feb 27, 2020
SAN DIEGO, February 26, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the...